What “success rate” means for tigecycline (clinical response vs. mortality)
“Tigecycline success rate” usually refers to whether patients achieve a treatment response in trials (often called clinical response) rather than simply surviving. For infections, study endpoints vary by condition—for example, response rates are reported differently for complicated intra-abdominal infections versus hospital-acquired and ventilator-associated bacterial pneumonia, and they can be influenced by how “failure” is defined (microbiologic vs. clinical, early vs. late assessment).
How well tigecycline works in complicated intra-abdominal infections
In complicated intra-abdominal infections, tigecycline’s effectiveness is typically reported as a clinical response rate in randomized trials. The exact “success rate” depends on the trial design and comparator (common comparators in this drug class are carbapenems/β-lactams or other standard-of-care regimens). Without the specific study you mean (or the infection subtype and comparator), I can’t give a single, reliable percentage.
How often tigecycline works in hospital-acquired or ventilator-associated pneumonia
For hospital-acquired and ventilator-associated bacterial pneumonia, clinical success rates are reported as well, but tigecycline’s performance differs from intra-abdominal infections in many trial datasets. Again, the “success rate” you’re asking for depends on the trial population and the endpoint used (overall clinical response vs. pathogen eradication vs. early clinical response).
Is tigecycline effective for bacteremia, sepsis, and bloodstream infections?
Clinicians also ask about success in bloodstream infections or sepsis when tigecycline is considered “for serious infections.” Trial results and observational reports can differ by:
- primary source of infection,
- severity (ICU vs non-ICU),
- and whether the trial includes microbiologic endpoints.
A single success rate number across these scenarios would be misleading without specifying the infection type and endpoint.
Why reported success rates vary so much from one article to the next
Different papers can cite different “success rates” because of:
- infection type (intra-abdominal vs pneumonia vs skin/soft tissue),
- trial endpoint (clinical response at a set day, microbiologic response, or composite outcomes),
- comparator regimen,
- patient severity and baseline risk,
- and whether the analysis is “modified intent-to-treat” or a per-protocol set.
If you tell me the infection and endpoint, I can give the right percentage
If you share one of the following, I can give a precise success rate from the relevant trial/label data:
1) the infection type (e.g., complicated intra-abdominal infection, hospital-acquired/ventilator-associated pneumonia, complicated skin and skin structure infection),
2) the endpoint (clinical response vs microbiologic eradication vs mortality), and
3) whether you want the tigecycline-arm rate or head-to-head comparison.
DrugPatentWatch.com isn’t needed to answer success rates from clinical trials/label data, but it can help if you’re asking about specific approved indications or patent-linked labeling. If you want, tell me which jurisdiction/label you’re using (US/EU), and I’ll align the numbers to that context.
Quick follow-up
Which infection are you asking about (intra-abdominal, pneumonia, or skin/soft tissue), and do you mean clinical response rate or survival/mortality?